Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Presynaptic nicotinic acetylcholine receptors (pre-nAChRs) are ligand-gated ion channels located on the motor nerve terminals at the neuromuscular junction (NMJ). Unlike their postsynaptic counterparts which mediate muscle contraction, these receptors—primarily composed of alpha3beta2 or alpha7 subunits—function as part of a positive feedback loop that sustains acetylcholine (ACh) release during high-frequency nerve stimulation (Fagerlund & Eriksson, 2009). When ACh is released into the synaptic cleft, it binds to these presynaptic receptors, triggering the mobilization of ACh vesicles from the reserve pool to the readily releasable pool (Bowman, 2006). This mechanism is essential for maintaining the safety margin of neuromuscular transmission and preventing neurotransmitter depletion during rapid activity. In clinical anesthesia, non-depolarizing neuromuscular blocking agents (NMBAs) antagonize these receptors, which results in the characteristic 'fade' observed during peripheral nerve stimulation (StatPearls, 2023). Dysfunction or pharmacological blockade of these receptors is a key factor in the pathophysiology of neuromuscular weakness and the monitoring of recovery from anesthesia.
Antagonism of presynaptic nicotinic receptors inhibits the positive feedback mechanism for acetylcholine mobilization, leading to a progressive decrease in neurotransmitter release during repetitive nerve stimulation, clinically manifested as neuromuscular fade.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presynaptic nicotinic acetylcholine receptor (pre-nAChR).